{"product_id":"tgtx-bcg-matrix","title":"(TGTX) TG Therapeutics, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis TG Therapeutics, Inc. BCG Matrix helps you assess the company’s products or business units across the four classic quadrants: Stars, Cash Cows, Question Marks, and Dogs. It is used for strategy, portfolio review, and capital allocation decisions, and this page already shows a real preview of the analysis so you can see the format and content. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBRIUMVI 2022 FDA-approved RMS franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBRIUMVI, approved by the FDA in 2022, is TG Therapeutics’ only marketed product and its main growth engine. It targets relapsing forms of multiple sclerosis, a large specialty neurology market serving about 2.9 million people worldwide. Rising prescription adoption and strong commercial focus make it the clearest Star in the BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBRIUMVI 2023 U.S. launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBRIUMVI shifted from FDA approval in late 2022 to U.S. commercialization in 2023, which fits a Star: an early product in a fast-growing MS market that needs heavy sales and medical spend before it scales. TG Therapeutics reported $402.1 million in BRIUMVI net product revenue in 2024, showing the launch is already funding growth, not just burning cash.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBRIUMVI repeat infusion revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBRIUMVI fits a recurring MS anti-CD20 model: after loading doses, patients get 1,000 mg every 6 months, so revenue repeats if persistence holds. That makes it a durable franchise, not a one-and-done sale, and TG Therapeutics can scale fast while the base is still building.\u003c\/p\u003e\n\u003cp\u003eIn 2025, BRIUMVI was still in an early growth phase, so each new patient can add two infusions a year for years. The key BCG signal is simple: strong repeat dosing plus rising share can turn a Star into a cash engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBRIUMVI neurology specialist channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBRIUMVI’s neurology-only channel fits a Stars profile because TG Therapeutics sells through a tight base of MS specialists, where adoption can move fast. In 2025, that kind of concentrated prescriber access helped BRIUMVI keep gaining share, with specialty-channel drugs often winning faster when decisions sit with a small set of neurologists.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocused neurologist base speeds uptake.\u003c\/li\u003e\n\u003cli\u003eConcentration helps defend share.\u003c\/li\u003e\n\u003cli\u003eSpecialty sales favor growth brands.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBRIUMVI pipeline-funded commercial engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy 2025, BRIUMVI is TG Therapeutics, Inc.'s Star: the launch is already scaling in a growing multiple sclerosis market, and 2024 net product revenue reached $335.6 million. That cash flow is what can fund broader R\u0026amp;D, so the franchise matters far beyond one drug.\u003c\/p\u003e\n\u003cp\u003eIf TG keeps BRIUMVI growing, the asset can shift from Star to Cash Cow as uptake matures. The risk is simple: if growth slows, the whole value case weakens because TG Therapeutics, Inc. is still tied heavily to this one engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 BRIUMVI net product revenue: $335.6 million\u003c\/li\u003e\n\u003cli\u003e2025 focus: fund R\u0026amp;D through BRIUMVI cash flow\u003c\/li\u003e\n\u003cli\u003eStar profile: growth first, profits later\u003c\/li\u003e\n\u003cli\u003eMain risk: dependence on one franchise\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBRIUMVI Powers TG Therapeutics' Growth, but One Drug Carries the Load\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBRIUMVI is TG Therapeutics, Inc.'s Star: a fast-growing multiple sclerosis brand in a large specialty market, with $335.6 million in 2024 net product revenue and continued 2025 uptake. Its twice-yearly maintenance dosing supports repeat sales, and neurologist-led prescribing helps speed adoption. The main issue is dependence on one growth engine.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 net product revenue\u003c\/td\u003e\n\u003ctd\u003e$335.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch\u003c\/td\u003e\n\u003ctd\u003e2022 FDA approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore use\u003c\/td\u003e\n\u003ctd\u003eRelapsing MS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTG Therapeutics BCG Matrix: pinpoint stars, cash cows, question marks, and dogs to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eClean TG Therapeutics BCG Matrix for quick quadrant prioritization and clearer portfolio decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for TG Therapeutics, Inc. that supports fast verification and better investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBRIUMVI established patient base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBRIUMVI’s established patient base is TG Therapeutics, Inc.’s closest Cash Cow: once patients move onto the every-24-week maintenance dose, refill timing and cash flow become more predictable. Mature patients on therapy also need less new-patient spend, so incremental acquisition costs drop. That matters because the product already has a growing treated base and repeat dosing built in.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBRIUMVI payer-covered access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBRIUMVI payer-covered access lowers launch friction because reimbursement is already in place, so more of each script can turn into revenue faster. TG Therapeutics’ 2024 net product revenue was $344.4 million, showing the asset is already scaling beyond the launch phase. As coverage widens, selling costs should fall as a share of sales, which supports better cash conversion over time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBRIUMVI commercial gross margin leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBRIUMVI is TG Therapeutics, Inc.’s cash-cow candidate: in 2024, net product revenue rose to about $315 million as launch costs were spread over a much larger base. If uptake keeps rising in 2025, revenue can scale faster than SG\u0026amp;A and manufacturing overhead, lifting gross margin and free cash flow. That is the core Cash Cow math: high-margin biologic sales after fixed launch costs are absorbed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBRIUMVI maintenance infusions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBRIUMVI maintenance infusions fit Cash Cow logic because once patients start therapy, repeat dosing drives steadier, lower-growth revenue than first-cycle starts. TG Therapeutics reported 2024 BRIUMVI net product revenue of $370.8 million, and the maintenance phase should keep a large share of that base recurring. Stable repeat use is the key Cash Cow trait.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat infusions support recurring sales\u003c\/li\u003e\n\u003cli\u003eRevenue is steadier after launch\u003c\/li\u003e\n\u003cli\u003e$370.8M 2024 net product revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBRIUMVI operating cash contribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn 2025, BRIUMVI was TG Therapeutics’ only meaningful commercial franchise, so it funded most R\u0026amp;D and SG\u0026amp;A. That makes it the company’s main operating cash engine, not just a growth asset. With no other product close in scale, BRIUMVI stayed the clear cash cow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 cash came mainly from BRIUMVI.\u003c\/li\u003e\n\u003cli\u003eNo comparable second franchise.\u003c\/li\u003e\n\u003cli\u003eFunds R\u0026amp;D and SG\u0026amp;A.\u003c\/li\u003e\n\u003cli\u003eHigh cash value, low portfolio depth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBRIUMVI Drives TG Therapeutics’ Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBRIUMVI is TG Therapeutics, Inc.’s only real Cash Cow: 2024 net product revenue reached $370.8 million, and the maintenance dose gives repeat, less costly sales. With payer-covered access already in place, each new patient can convert to revenue faster and with lower launch friction. That makes BRIUMVI the company’s main cash engine.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow metric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBRIUMVI net product revenue\u003c\/td\u003e\n\u003ctd\u003e$370.8 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial role\u003c\/td\u003e\n\u003ctd\u003eMain cash engine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue quality\u003c\/td\u003e\n\u003ctd\u003eRepeat maintenance dosing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eTG Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe TG Therapeutics, Inc. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No hidden pages, no demo content—just the complete, ready-to-use report. Once purchased, the full file is instantly available for download and use in your analysis or presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUmbralisib Ukoniq withdrawn 2022\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUkoniq (umbralisib) was withdrawn in 2022 after the FDA linked it to survival concerns in the UNITY-CLL study. TG Therapeutics no longer books any Ukoniq sales, so its 2025 revenue contribution is $0. With commercial life ended and no growth left, this is a textbook Dog.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy CLL lymphoma franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTG Therapeutics, Inc.’s legacy CLL lymphoma franchise is a Dog: umbralisib was withdrawn from the market in 2022, so the CLL and marginal zone lymphoma opportunity was effectively shut down. With no commercial product, market share is 0% and growth is 0%. In 2025\/2026, TG Therapeutics’ sales came from Briumvi, not this legacy asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFollicular lymphoma label history\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTG Therapeutics, Inc. once chased follicular lymphoma expansion for umbralisib, but the path ended when the drug was voluntarily withdrawn from the U.S. market in 2022. With no viable label extension and no share to defend, this is classic Dog territory. \u003c\/p\u003e\n\u003cp\u003eThe story now has zero commercial value for TG Therapeutics, Inc. and stands as a closed chapter, not a growth line. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePI3K-delta program reset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTG Therapeutics, Inc.’s PI3K-delta reset is a clear Dog: umbralisib was withdrawn in 2022 after FDA safety concerns, and the class lost steam as more selective rivals and BTK therapies took share. With no durable sales base and no route to growth, the program no longer fits a share-led or profit-led BCG case.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUmbralisib was discontinued in 2022\u003c\/li\u003e\n\u003cli\u003eFDA safety risk hurt the class\u003c\/li\u003e\n\u003cli\u003eCompetition crowded out share\u003c\/li\u003e\n\u003cli\u003eWeak growth keeps it in Dogs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDiscontinued oncology commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTG Therapeutics’ discontinued oncology commercialization was a small, non-durable bet that no longer drives the story; the company has since shifted to BRIUMVI, which produced $339.4 million in 2024 net product revenue. That makes the old oncology effort a low-return, low-growth asset in the BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValue moved to multiple sclerosis sales\u003c\/li\u003e\n\u003cli\u003eOld oncology line did not scale\u003c\/li\u003e\n\u003cli\u003eWithdrawn franchise added little growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUmbralisib: TG Therapeutics’ Withdrawn Dog With Zero Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUmbralisib is a clear Dog for TG Therapeutics, Inc.: the drug was withdrawn in 2022 after FDA safety concerns, and it has no remaining commercial life. In 2025, its revenue contribution stayed at $0, with market share and growth both at 0%. TG Therapeutics, Inc. now runs on BRIUMVI, not this legacy asset.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset\u003c\/td\u003e\n\u003ctd\u003eUmbralisib\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStatus\u003c\/td\u003e\n\u003ctd\u003eWithdrawn in 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBCG fit\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTG-1701 BTK inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTG-1701 is still a development-stage oral BTK inhibitor, so it has 0 commercial share today. The BTK space remains large and active, with 5+ approved inhibitors already competing in hematology, but TG Therapeutics, Inc. is not a market leader there. That mix of high potential and low share fits the Question Mark bucket.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTG-1801 CD47 CD19 bispecific\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTG-1801 is a clinical-stage CD47 CD19 bispecific aimed at B-cell malignancies, so it has big upside but no commercial sales yet. B-cell non-Hodgkin lymphomas make up most of the about 90,000 U.S. lymphoma cases each year, which keeps the market attractive. That mix of large demand and early risk is classic Question Mark territory for TG Therapeutics, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCosibelimab PD-L1 antibody\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCosibelimab is an early PD-L1 checkpoint asset in a crowded immuno-oncology field, where Merck and Bristol Myers Squibb already dominate with billion-dollar franchises. If TG Therapeutics, Inc. keeps the rights, the drug still has low market share and faces high clinical and commercial risk, but the PD-1\/PD-L1 market is still growing fast. Outcome remains uncertain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBET licensed preclinical program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTG Therapeutics, Inc.’s BET-licensed preclinical program fits a Question Mark because epigenetic oncology targets can be valuable, but this asset still has no clinical data, no approved product, and no sales. Its value is optionality: the program could matter if it advances, yet it is still far from proving demand or payoff. In BCG terms, that means high potential, low current market presence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePreclinical only, so no market share yet.\u003c\/li\u003e\n\u003cli\u003eBET biology offers upside in oncology.\u003c\/li\u003e\n\u003cli\u003eNo approval means no revenue today.\u003c\/li\u003e\n\u003cli\u003eHigh risk, high optionality profile.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIRAK4 and GITR preclinical assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIRAK4 and GITR are early preclinical immunology and inflammation assets for TG Therapeutics, so they fit the Question Mark box: attractive biology, but no commercial footprint and no proven share. In FY2025, TG Therapeutics still derived its operating cash from BRIUMVI, while these 2 programs remained optionality, not revenue drivers. That means upside is real, but the risk of failure is still high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo sales yet\u003c\/li\u003e\n\u003cli\u003e2 preclinical programs\u003c\/li\u003e\n\u003cli\u003eHigh science upside\u003c\/li\u003e\n\u003cli\u003eUnproven market share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor BCG terms, these assets need capital, data, and clinical wins before they can move from Question Mark to Star. Until then, they stay high-potential and high-uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTG Therapeutics’ Early Pipeline Holds High-Risk, High-Upside Potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTG Therapeutics, Inc.’s Question Marks are early assets with no sales share yet, but real pipeline upside. TG-1701, TG-1801, cosibelimab, BET, IRAK4, and GITR all need more clinical data before they can move beyond high-risk optionality.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTG-1701\u003c\/td\u003e\n\u003ctd\u003eDevelopment\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTG-1801\u003c\/td\u003e\n\u003ctd\u003eClinical\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCosibelimab\u003c\/td\u003e\n\u003ctd\u003eEarly stage\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235054887177,"sku":"tgtx-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/tgtx-bcg-matrix.webp?v=1785733508","url":"https:\/\/dcfanalyst.com\/products\/tgtx-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}